The Patent Finder

Maintenance fees coming due

Tusk Therapeutics Ltd.

9 maintenance fees come due in the 12 months from Nov 17, 2026, the next on Jan 11, 2027. Unpaid by Jul 12, 2027, that one lapses early.
A maintenance fee does not end a patent on its due date. It falls due at 3.5, 7.5 and 11.5 years from grant, and the patent lapses only if the fee is still unpaid at the end of the six month grace period that follows.
PatentTitleHolderStatusFee dueLapses if unpaidExpiresConfidence
US 11,697,688ANTI-CD25 for Tumour Specific Cell Depletion
In force
Fee due Jan 11, 2027
Lapses if unpaid Jul 12, 2027
 · High confidence
Cancer Research Technology Limited and Tusk Therapeutics Ltd.In forceJan 11, 2027Jul 12, 2027High confidence
US 11,787,866ANTI-CD25 Antibody Agents
In force
Fee due Apr 17, 2027
Lapses if unpaid Oct 18, 2027
 · High confidence
Tusk Therapeutics, Ltd.In forceApr 17, 2027Oct 18, 2027High confidence
US 11,802,160ANTI-CD25 Antibody Agents
In force
Fee due Apr 30, 2027
Lapses if unpaid Nov 1, 2027
 · Low confidence
Tusk Therapeutics Ltd.In forceApr 30, 2027Nov 1, 2027Low confidence
US 11,802,161ANTI-CD25 for Tumour Specific Cell Depletion
In force
Fee due Apr 30, 2027
Lapses if unpaid Nov 1, 2027
 · High confidence
Cancer Research Technology Limited and Tusk Therapeutics Ltd.In forceApr 30, 2027Nov 1, 2027High confidence
US 11,814,434ANTI-CD25 for Tumour Specific Cell Depletion
In force
Fee due May 14, 2027
Lapses if unpaid Nov 15, 2027
 · High confidence
Cancer Research Technology Limited and Tusk Therapeutics Ltd.In forceMay 14, 2027Nov 15, 2027High confidence
US 11,851,494ANTI-CD25 for Tumour Specific Cell Depletion
In force
Fee due Jun 26, 2027
Lapses if unpaid Dec 27, 2027
 · High confidence
Cancer Research Technology Limited and Tusk Therapeutics Ltd.In forceJun 26, 2027Dec 27, 2027High confidence
US 11,873,341ANTI-CD25 for Tumour Specific Cell Depletion
In force
Fee due Jul 16, 2027
Lapses if unpaid Jan 18, 2028
 · High confidence
Cancer Research Technology Limited and Tusk Therapeutics Ltd.In forceJul 16, 2027Jan 18, 2028High confidence
US 11,879,014A Method of Treating Cancer or Depleting Regulatory T Cells in a Subject by Administering a Human IGG1 ANTI-CD25 Antibody
In force
Fee due Jul 23, 2027
Lapses if unpaid Jan 24, 2028
 · High confidence
Cancer Research Technology Limited and Tusk Therapeutics Ltd.In forceJul 23, 2027Jan 24, 2028High confidence
US 11,919,960ANTI-CD25 Antibody Agents
In force
Fee due Sep 5, 2027
Lapses if unpaid Mar 6, 2028
 · High confidence
Cancer Research Technology Limited and Tusk Therapeutics LTC.In forceSep 5, 2027Mar 6, 2028High confidence
9 of 9 patents shown. Soonest fee due date first, then patent number.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited